Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2011-11-29 Regulatory Filings
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings
2011-11-29 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 18, 2011. It reports the entry into a material definitive agreement, specifically lease agreements for office and manufacturing space. The content is an announcement of a corporate event rather than a full financial report or detailed financial data. The document length is 3082 characters, which is relatively short and consistent with a current report announcement. There is no financial statement or detailed analysis present. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2011-11-25 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated November 7, 2011. The main content is about the appointment of a new senior executive, Russell P. Wilson, as Senior Vice President, Business Development, including details of his employment agreement, compensation, and background. There is no financial data or report content, but rather an announcement of a management change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length is about 5405 characters, which is sufficient to contain detailed information about the appointment. Therefore, the correct classification is MANG with high confidence.
2011-11-10 English
FORM 10-Q
Interim / Quarterly Report 9M 2011
2011-11-08 English
AMENDMENT TO FORM 10-Q
Interim / Quarterly Report Q1 2011
2011-11-04 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated September 7, 2011, for Novavax, Inc. The key content is the departure of a senior executive, John Trizzino, who resigned as Senior Vice President, Business Development. The document specifically mentions the resignation and recruitment for a replacement. This matches the description of announcements related to changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. It is clearly an announcement of management change, fitting the Board/Management Information (MANG) category. The document length is short and focused solely on management change, confirming the classification with high confidence.
2011-09-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.